Zimbabwe has turned down a major American healthcare agreement worth $367m (272 million pounds) over five years because of the United States' request for confidential data.
This rejection became public following a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official representative later explained that the US was requesting biological samples for scientific study and profit but refused to share the benefits from future medical innovations.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for continued dialogue to secure a agreement suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court suspended a similar deal with the US after concerns were raised about the security of Kenyans' medical information.
After returning to office last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to enhance transparency and responsibility.
According to reports, 16 nations in Africa have to date signed similar agreements, constituting more than $18.3bn in committed funds.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment via American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," his statement read.
"Effectively, our country would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our people should a future health crisis emerge."
National Interest and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining frameworks previously set up via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This framework is intended to guarantee that when a country provides its information, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how future collaboration could be designed in a way that honours the independence and dignity of each country."
Health Experts Reaction
A leading public health body expressed it understood the government's concerns, but suggested that negotiations need to persist since much of the country's HIV programmes relied on external financing.
"Where specific concerns arise, including those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," the group said.
This impasse emphasises the ongoing challenges between accepting much-needed international aid and protecting a country's data in an ever more data-driven world.